全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Daan Nevens , Isabelle Kindts , Noémie Defourny ...
来源:[J].Radiotherapy and Oncology(IF 4.52), 2020, Vol.145, pp.215-222
摘要:Abstract(#br)Introduction(#br)There is a steady rise in Stereotactic Body RadioTherapy (SBRT) utilization in oligometastatic disease (OMD). This may generate important financial consequences for radiotherapy budgets. The National Institute for Health and Disability Insurance o...
作者:André Diamant , Veng Jean Heng , Avishek Chatterjee ...
来源:[J].Radiotherapy and Oncology(IF 4.52), 2020, Vol.144, pp.201-208
摘要:Abstract(#br)Background and Purpose(#br)Previous literature suggests that the dose proximally outside the PTV could have an impact on the incidence of distant metastasis (DM) after SBRT in stage I NSCLC patients. We investigated this observation (along with local failure) in...
作者:Naghmeh Isfahanian , Himanshu Lukka , Ian Dayes ...
来源:[J].Clinical Genitourinary Cancer(IF 1.429), 2019
摘要:... Stereotactic body radiotherapy (SBRT) is a promising, non-invasive alternative to brachytherapy. However, its impact on patient quality of life (QoL) and RT-associated toxicity has not been investigated in a randomized setting. In this study, we investigate SBRT as a boost tr...
作者:Paul Kreinbrink , Philip Blumenfeld , George Tolekidis ...
来源:[J].Journal of Geriatric Oncology(IF 1.118), 2017, Vol.8 (5), pp.351-355
摘要:Abstract(#br)Objective(#br)Stereotactic body radiotherapy (SBRT) for early-stage non-small-cell lung cancer (NSCLC) is the standard of care in medically inoperable patients. In very elderly patients, previous studies have shown SBRT to offer excellent local control, though wit...
作者:R.J. Klement , J. Hoerner-Rieber , S. Adebahr ...
来源:[J].Radiotherapy and Oncology(IF 4.52), 2018, Vol.127 (2), pp.246-252
摘要:Abstract(#br)Background(#br)Stereotactic body radiotherapy (SBRT) for oligometastatic disease is characterized by an excellent safety profile; however, experiences are mostly based on treatment of one single metastasis. It was the aim of this study to evaluate safety and efficacy...
作者:Vinicius Ernani , Adams Kusi Appiah , Alissa Marr ...
来源:[J].Journal of Thoracic Oncology(IF 4.473), 2018
摘要:Abstract(#br)Introduction(#br)Stereotactic body radiation therapy (SBRT) is commonly used to treat nonsurgical patients with early-stage NSCLC. There are no prospective data on the role of adjuvant chemotherapy in this setting.(#br)Methods(#br)Patients (≥18 years) diagnosed w...
作者:William R. Kennedy , Prashant Gabani , John Nikitas ...
来源:[J].Radiotherapy and Oncology(IF 4.52), 2020, Vol.142, pp.230-235
摘要:Abstract(#br)Purpose(#br)Optimal management of isolated local recurrences after stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) is unknown and literature describing repeat SBRT for in-field recurrences after initial SBRT are sparse. We...
作者:E. Villaggi , M. Esposito , V. Hernández ...
来源:[J].Physica Medica(IF 1.167), 2018, Vol.56, pp.81-81
摘要:...(#br)Methods(#br)Each center was provided with 5 anonymized CTs with pre-delineated volumes and was asked to create SBRT plans according to pre-set dose constraints. Dose prescription to PTV was 7 Gy × 5 fr. Dosimetric parameters, modulation index (MItotal) and dynamic param...
作者:Jan Nyman , Andreas Hallqvist , Jo-Åsmund Lund ...
来源:[J].Radiotherapy and Oncology(IF 4.52), 2016, Vol.121 (1), pp.1-8
摘要:Abstract(#br)Background(#br)Stereotactic body radiotherapy (SBRT) has been introduced for small lung tumors due to excellent local control and few side effects, even though there are no comparative studies. SPACE (Stereotactic Precision And Conventional radiotherapy Evaluation) ...
作者:Mirjana Josipovic , Gitte Fredberg Persson , Jonas Scherman Rydhög ...
来源:[J].Physica Medica(IF 1.167), 2018, Vol.56, pp.50-57
摘要:Abstract(#br)Purpose(#br)Evaluating performance of modern dose calculation algorithms in SBRT and locally advanced lung cancer radiotherapy in free breathing (FB) and deep inspiration breath hold (DIBH).(#br)Methods(#br)For 17 patients with early stage and 17 with locally advan...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×